source
- Oxford biotech OMass Therapeutics secures $310 million to advance genetic adrenal disorder programOxford-based OMass Therapeutics announced a $310 million private financing round, one of the largest recent fundraises for a UK biotech. The capital will fund the development of therapies targetin…
- AstraZeneca signs $1.5B AI partnership with insitro to discover liver and heart disease targetsAstraZeneca announced a partnership with insitro, a biotech that uses artificial intelligence, with an upfront payment of $40 million and potential milestones up to $1.46 billion. The collaboratio…